Urogen Pharma Ltd.

Yulia Hionidi

Marina Konorty

Omer Tsipori

A kit provides for sustained release of therapeutic agents for local treatment of cancer diseases by providing lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel to be applied to affected tissue. The hydrogel comprises poloxamer 407, hydroxypropylmethylcellulose and water. A lyophilized composition comprises mitomycin C and urea as a bulking agent.

Material and method for treating cancer

Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.

Growing community of inventors

Petah Tiqwa, Israel

Yulia Hionidi